BPC-157 and TB-500: The Complete Research Stack Guide 2026
The BPC-157 and TB-500 combination is one of the most consistently discussed stacks in the research peptide community. Walk into any serious biohacking forum or longevity discussion group in 2026 and you will find this pairing referenced more than almost any other combination — not because of marketing, but because the two compounds have genuinely complementary mechanisms and a substantial volume of preclinical research backing their individual applications.
This guide covers what the research says about each compound individually, why researchers combine them, current pricing across our 40+ verified supplier database, and how to source both with proper documentation. Everything here is framed for research purposes — these are not approved therapeutic agents, and this is not medical advice.
BPC-157: What the Research Shows
BPC-157, or Body Protection Compound 157, is a synthetic pentadecapeptide (15 amino acids) derived from a protein sequence found in human gastric juice. It has been studied in preclinical research since the 1990s and has one of the larger bodies of animal-model evidence of any research peptide currently available.
Primary Research Areas
Tendon and ligament healing. BPC-157 is among the most studied compounds for tendon repair in animal models. Research has consistently shown accelerated tendon-to-bone healing, increased fibroblast migration, and upregulation of growth hormone receptors at injury sites. Studies in rat models of Achilles tendon rupture and rotator cuff injury showed significantly faster healing compared to controls.
Gastrointestinal repair. This is where BPC-157's gastric origin becomes relevant. Research has studied it extensively for gut lining repair, including models of inflammatory bowel conditions, gastric ulcers, and leaky gut. The compound appears to promote angiogenesis (new blood vessel formation) in GI tissue and modulate tight junction proteins that maintain gut barrier integrity.
Muscle repair. Animal model research shows BPC-157 accelerates healing in crush-injury and incision-wound muscle models. The mechanism overlaps with its tendon effects — upregulation of growth factor signaling and promotion of cellular migration to injury sites.
Anti-inflammatory properties. Multiple studies have documented BPC-157's anti-inflammatory effects across tissue types. The mechanism is not fully characterized but appears to involve modulation of the nitric oxide system and cytokine pathways.
Neuroprotective effects. More recent research has explored BPC-157 in neurological damage models, including traumatic brain injury and dopaminergic neuron protection. This is an emerging research area with fewer published studies than the tendon and GI work.
Key Research Characteristics
BPC-157 is notable for being stable in human gastric acid — an unusual property for a peptide. This has made it a subject of research for oral administration, particularly for gut-related applications. Subcutaneous and intramuscular administration provide more reliable systemic bioavailability for non-GI applications.
Typical research doses in animal models translate to roughly 200–500mcg per administration, 1–2 times daily, over 4–12 week cycles. These are research reference points, not dosing recommendations.
TB-500: What the Research Shows
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), specifically a fragment corresponding to the actin-binding domain of the full protein. Thymosin Beta-4 is a naturally occurring protein found at high concentrations in blood platelets and wound fluid — it plays a fundamental role in the body's repair response.
Primary Research Areas
Systemic tissue repair. Unlike BPC-157, which tends to exert its strongest effects near the administration site, TB-500 circulates systemically. Research in animal models shows it can reach and support repair processes in multiple tissue types throughout the body from a single injection site.
Cardiac tissue protection. TB-500 has been studied in cardiac injury models — specifically ischemia-reperfusion injury — with results suggesting cardioprotective effects through promotion of new blood vessel formation and reduction of cardiomyocyte death. This is one of the most clinically interesting areas of TB-500 research.
Flexibility and anti-inflammatory effects. Research in equine models (horses have been the subject of significant TB-500 research) shows improvement in soft tissue flexibility and reduction of injury-related inflammation. This has driven interest in the compound among researchers studying connective tissue health.
Hair regrowth. Some animal model research has documented hair regrowth with TB-500 in specific models. This appears to be a secondary effect rather than a primary research focus.
Muscle and tendon healing. Like BPC-157, TB-500 shows accelerated healing in muscle and tendon injury models. The mechanism is different — TB-500 works primarily through actin-binding and promotion of cellular migration — but the outcomes in healing models overlap considerably.
Key Research Characteristics
TB-500's systemic distribution is its defining characteristic relative to BPC-157. Animal research uses a loading protocol: higher frequency dosing for 4–6 weeks followed by a reduced maintenance schedule. Standard research reference doses are approximately 2–2.5mg twice weekly during loading, then once weekly for maintenance.
Why Researchers Combine BPC-157 and TB-500
The rationale for stacking these compounds is mechanistic complementarity rather than additive effect from using more of the same thing.
Local vs. systemic coverage. BPC-157 acts most potently near the administration site and in the gut. TB-500 distributes systemically. Together, they cover both local and systemic healing pathways simultaneously.
Different primary mechanisms. BPC-157's effects are mediated primarily through growth hormone receptor upregulation and nitric oxide system modulation. TB-500 works primarily through actin binding and cell migration promotion. Research using both compounds targets multiple independent pathways rather than doubling down on one.
Complementary tissue targets. BPC-157 has the strongest evidence base in GI tissue and tendons specifically. TB-500 has stronger evidence in cardiac tissue and systemic soft tissue. For researchers studying broad tissue repair, the combination covers ground that neither compound covers alone.
Angiogenesis from two directions. Both compounds promote angiogenesis (new blood vessel formation) through different signaling pathways. Some researchers hypothesize this may produce greater net vascularization at repair sites than either compound alone, though direct combination studies are limited.
This stack is not theoretical — it appears regularly in research protocols specifically because the mechanism overlap is partial rather than complete, making the combination more than the sum of its parts in targeted tissue repair research.
Price Comparison: BPC-157 and TB-500 in 2026
Both BPC-157 and TB-500 are among the most widely stocked compounds in the research peptide market — available from nearly every supplier in our index. This competition keeps pricing relatively stable and gives researchers good access to third-party verified options.
Current Market Pricing Overview
BPC-157 (10mg vial, in-stock suppliers):
- Low end: approximately $30–$35 (Alpha Omega, Flawless Compounds, True Peptide)
- Mid range: approximately $40–$55 (majority of suppliers)
- High end: approximately $65–$99 (premium or smaller-catalog suppliers)
TB-500 (10mg vial, in-stock suppliers):
- Low end: approximately $34–$45 (Alpha Omega, Welli Labs, True Peptide)
- Mid range: approximately $46–$65 (majority of suppliers)
- High end: approximately $70–$85+ (premium or smaller-catalog suppliers)
For current per-mg prices sorted by value, see the live comparison pages:
Suppliers With Third-Party COAs for This Stack {#sourcing}
If you're sourcing both compounds and want independent laboratory verification on each, these suppliers offer third-party COAs and currently stock both BPC-157 and TB-500:
| Supplier | 3P COA | BPC-157 | TB-500 | Discount Code |
|---|---|---|---|---|
| Ascension Peptides | Yes | In Stock | Check live | Yes |
| Amino Club | Yes | In Stock | In Stock | Yes (20%+) |
| LA Peptides | Yes | In Stock | In Stock | Yes |
| Midwest Peptide | Yes | In Stock | In Stock | Yes |
| Hydro Research | Yes | In Stock | In Stock | Yes (30%) |
| Riptide Wellness | Yes | In Stock | In Stock | No |
| Southern Aminos | Yes | In Stock | In Stock | No |
| Polaris Peptides | Yes | In Stock | In Stock | No |
Stock status changes frequently. Use the live comparison tool to verify current availability before ordering.
Buying Both From One Supplier
Ordering both compounds from the same supplier reduces shipping costs, which can meaningfully affect total cost at common order sizes. Some suppliers offer stack kits combining BPC-157 and TB-500 — break down the kit price to per-mg for each compound before assuming it's a better deal than buying separately.
Frequently Asked Questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic peptide derived from human gastric juice protein. TB-500 is a fragment of Thymosin Beta-4, a naturally occurring protein found in wound fluid and platelets. Their mechanisms are different — BPC-157 acts primarily locally through growth hormone receptor and nitric oxide pathways; TB-500 distributes systemically through actin-binding and cell migration. Both are studied for tissue repair, but they target different pathways and tissue distributions, which is why researchers combine them.
Why is this stack so popular?
Volume of supporting research (both compounds have extensive preclinical data), complementary mechanisms that don't simply duplicate each other, and practical availability — both are widely stocked by most research peptide suppliers at accessible price points. The combination has a legitimate mechanistic rationale rather than being a trend-driven pairing.
Which compound should be prioritized for specific research applications?
BPC-157 is the compound with stronger evidence specifically for gut/GI tissue research and local tendon repair. TB-500 is typically prioritized for systemic repair, cardiac tissue research, and applications where broad systemic distribution is desired. For comprehensive tissue repair research covering multiple sites, the combination is the standard approach.
Are there suppliers who carry pre-mixed BPC-157 + TB-500 combinations?
Some suppliers offer stack kits. Check the main comparison tool — search "BPC" or "TB-500" and look for combined listings. Always verify the total compound content (mg of each peptide) when evaluating these products against per-mg pricing on individual vials.
How does pricing for this stack compare to GLP-1 compounds?
BPC-157 and TB-500 are among the more affordable compounds in the research peptide market. At current prices, a research cycle supply of both compounds typically costs less than a comparable supply of GLP-1 compounds like Semaglutide or Tirzepatide. The healing compound category is also more price-competitive across suppliers, meaning the spread between cheapest and most expensive options is smaller.
All compounds are sold by listed suppliers for research purposes only and are not intended for human use, food, or drug applications. This content is informational and does not constitute medical advice. Bestpepprices.com does not sell compounds and is not compensated by any supplier for rankings or coverage.
Compare BPC-157 prices → | Compare TB-500 prices → | All healing compounds →
Compare live prices across 60+ verified research peptide suppliers